These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9370947)

  • 1. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer.
    Koivisto P; Visakorpi T; Rantala I; Isola J
    J Pathol; 1997 Sep; 183(1):51-6. PubMed ID: 9370947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer.
    Koivisto PA; Rantala I
    J Pathol; 1999 Jan; 187(2):237-41. PubMed ID: 10365100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
    Laitinen S; Martikainen PM; Tammela TL; Visakorpi T
    Eur Urol; 2007 Sep; 52(3):725-32. PubMed ID: 17141945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor amplification is associated with increased cell proliferation in prostate cancer.
    Haapala K; Kuukasjärvi T; Hyytinen E; Rantala I; Helin HJ; Koivisto PA
    Hum Pathol; 2007 Mar; 38(3):474-8. PubMed ID: 17217995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in cell proliferation and apoptosis during local progression of prostate cancer.
    Kaibuchi T; Furuya Y; Akakura K; Masai M; Ito H
    Anticancer Res; 2000; 20(2B):1135-9. PubMed ID: 10810410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification.
    Koivisto P
    Prostate Cancer Prostatic Dis; 1997 Sep; 1(1):21-25. PubMed ID: 12496929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
    Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
    J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate.
    Landström M; Damber JE; Bergh A
    Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer.
    Furuya Y; Kawauchi Y; Fuse H
    Anticancer Res; 2003; 23(1B):577-81. PubMed ID: 12680149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
    Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
    Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P; So A; Kojima S; Signaevsky M; Beraldi E; Fazli L; Hurtado-Coll A; Yamanaka K; Gleave M
    Cancer Res; 2004 Sep; 64(18):6595-602. PubMed ID: 15374973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
    Ohlson N; Bergh A; Nygren K; Stattin P; Wikström P
    Eur Urol; 2006 Apr; 49(4):675-83. PubMed ID: 16387414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.